Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$463.15 USD
+1.39 (0.30%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $463.00 -0.15 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$463.15 USD
+1.39 (0.30%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $463.00 -0.15 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod
by Arpita Dutt
Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.
Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.
Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Is Celgene (CELG) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.
Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
Vertex's (VRTX) Kalydeco is expected to generate increased revenues following its label expansion in the third quarter of 2017.
4 of the Most Efficient Stocks to Buy Now
by Tirthankar Chakraborty
Companies with favorable efficiency levels are likely to be on investors' radar irrespective of market conditions.
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
by Arpita Dutt
Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks.
Will Quest Diagnostics (DGX) Disappoint in Q3 Earnings?
by Zacks Equity Research
The overall soft industry trends leading to low volume environment may continue to put a dampener on Quest Diagnostics (DGX) in Q3. The reimbursement scenario also remains a major cause for concern.
Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Cystic fibrosis is a life-shortening genetic disorder affecting 75,000 youth and Vertex is leading treatment with multiple breakthroughs
Is a Beat in Store for Abbott (ABT) This Earnings Season?
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.
Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
by Arpita Dutt
With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.
Amgen Label Expansion Application for Prolia Accepted by FDA
by Zacks Equity Research
Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).
Why the Earnings Streak Will Continue for Vertex Pharmaceuticals (VRTX)
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.
Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
by Arpita Dutt
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation
by Arpita Dutt
Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.
3 Top-Ranked Big Biotech Stocks to Buy Now
by Zacks Equity Research
With biotech stocks on a tear, here we have picked three of the biggest biotech companies which look well poised for growth and can be added to one's portfolio
Mallinckrodt (MNK) Closes InfaCare Pharmaceutical Buyout
by Zacks Equity Research
Mallinckrodt (MNK) acquires privately-held InfaCare Pharmaceutical Corporation to diversify portfolio.
Top Stock Reports for Goldman Sachs, PepsiCo and Johnson & Johnson
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Goldman Sachs Group Inc (GS), PepsiCo, Inc. (PEP) and Johnson & Johnson (JNJ)
Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues
by Arpita Dutt
Key highlights this week include Amgen's (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept's Ocaliva.
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
by Arpita Dutt
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard
by Zacks Equity Research
The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard